AI Summary
We reviewed 36 live results for vegf inhibitor and narrowed them down to the 3 options that look most worth comparing first.
The strongest themes across this short list are Oncology and Biosimilar.
Comparison Table
Recommended
MVASI (bevacizumab-awwb)
Source: Amgen Inc.
Description
MVASI is a recombinant humanized monoclonal antibody that serves as a Vascular Endothelial Growth Factor (VEGF) inhibitor and biosimilar to Avastin. It is provided as a sterile, preservative-free solution for intravenous infusion in 100 mg/4 mL and 400 mg/16 mL single-dose vials. This oncology treatment is indicated for patients with metastatic colorectal cancer (mCRC), non-squamous non-small cell lung cancer (NSCLC), recurrent glioblastoma, metastatic renal cell carcinoma (mRCC), cervical cancer, and various stages of ovarian cancer.
Best for
oncology patients, metastatic colorectal cancer treatment, NSCLC first-line therapy, recurrent glioblastoma management and combination chemotherapy regimens
View Details
Rating
Cosentyx
Source: Novartis Malaysia
Description
Cosentyx (Secukinumab) is an interleukin inhibitor prescribed for plaque psoriasis and psoriatic arthritis. It is supplied as a 150 mg/mL solution for injection in a pre-filled pen or syringe.
Best for
plaque psoriasis, psoriatic arthritis and interleukin inhibition
View Details
Rating
Rinvoq (upadacitinib)
Source: AbbVie Philippines Inc.
Description
Rinvoq is a prescription medication containing upadacitinib, a selective and reversible JAK inhibitor used to treat moderate to severe active rheumatoid arthritis, psoriatic arthritis, and atopic dermatitis. As the original manufacturer, AbbVie ensures the availability of this specialty drug in the Philippines for patients requiring advanced immunological therapy.
Best for
Rheumatoid arthritis treatment, Psoriatic arthritis patients, Moderate to severe atopic dermatitis and Specialized immunological care
View Details
Rating
| Compare | MVASI (bevacizumab-awwb) | Cosentyx | Rinvoq (upadacitinib) |
|---|---|---|---|
| Source | Amgen Inc. | Novartis Malaysia | AbbVie Philippines Inc. |
| Description | MVASI is a recombinant humanized monoclonal antibody that serves as a Vascular Endothelial Growth Factor (VEGF) inhibitor and biosimilar to Avastin. It is provided as a sterile, preservative-free solution for intravenous infusion in 100 mg/4 mL and 400 mg/16 mL single-dose vials. This oncology treatment is indicated for patients with metastatic colorectal cancer (mCRC), non-squamous non-small cell lung cancer (NSCLC), recurrent glioblastoma, metastatic renal cell carcinoma (mRCC), cervical cancer, and various stages of ovarian cancer. | Cosentyx (Secukinumab) is an interleukin inhibitor prescribed for plaque psoriasis and psoriatic arthritis. It is supplied as a 150 mg/mL solution for injection in a pre-filled pen or syringe. | Rinvoq is a prescription medication containing upadacitinib, a selective and reversible JAK inhibitor used to treat moderate to severe active rheumatoid arthritis, psoriatic arthritis, and atopic dermatitis. As the original manufacturer, AbbVie ensures the availability of this specialty drug in the Philippines for patients requiring advanced immunological therapy. |
| Best for | oncology patients, metastatic colorectal cancer treatment, NSCLC first-line therapy, recurrent glioblastoma management and combination chemotherapy regimens | plaque psoriasis, psoriatic arthritis and interleukin inhibition | Rheumatoid arthritis treatment, Psoriatic arthritis patients, Moderate to severe atopic dermatitis and Specialized immunological care |
| Tags | |||
| Action | View Details | View Details | View Details |
| Rating |
AI Recommendation
If you want the most balanced option to start with, I recommend:
"MVASI (bevacizumab-awwb) from Amgen Inc.."
I picked this because MVASI is an FDA-approved biosimilar providing a clinically equivalent therapeutic option for multiple types of advanced and metastatic cancers.
Share this search
Related Finds